Cited by 75Nanoparticle-Based Drug DeliveryNanotechnology research and applicationsBarrier Structure and Function Studies

Therapeutics, imaging and toxicity of nanomaterials in the central nervous system.

Nunes, Antonio, Al-Jamal, Khuloud T., Kostarelos, Kostas·2012·Journal of Controlled Release

Abstract

Treatment and diagnosis of neurodegenerative diseases and other CNS disorders are nowadays considered some of the most challenging tasks in modern medicine. The development of effective strategies for the prevention, diagnosis and treatment of CNS pathologies require better understanding of neurological disorders that is still lacking. The use of nanomaterials is thought to contribute to our further understanding of the CNS and the development of novel therapeutic and diagnostic modalities for neurological interventions. Even though the application of nanoparticles in neuroscience is still embryonic, this article attempts to illustrate the use of different types of nanomaterials and the way in which they have been used in various CNS applications in an attempt to limit or reverse neuropathological processes.

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2012.03.026

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Nanotechnology provides alternative ways to treat multiple sclerosis pathology related to non-genetic manipulations of signaling pathways in vivo.

    “It provides alternative ways to treat MS pathology related to non-genetic manipulations of signaling pathways in vivo”

    From Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs (2020) · cites this paper as Nunes et al., 2012

Cites

Flagged first, then by citations

1 of the 134 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Nunes, A., Al-Jamal, K. T., & Kostarelos, K.
Affiliations
UCL School of Pharmacy (GB)
Corresponding author
Kostarelos, Kostas
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2012-07
Volume
161
Issue
2
Pages
290-306
ISSN
0168-3659 (ISSN-L)
OpenAlex
W2049105605
Cited by
75
References
134
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 3 · 2021: 1 · 2020: 4 · 2019: 1 · 2018: 5 · 2017: 7 · 2016: 4 · 2015: 12 · 2014: 9 · 2013: 13 · 2012: 3
FWCI
0.61
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Controlled Release (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanotechnology research and applications
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords
nanomaterials, central nervous system, neurodegenerative diseases, nanoparticles, neuroimaging, nanomedicine, brain drug delivery, neurological disorders
MeSH terms
Animals, Central Nervous System Diseases, Diagnostic Imaging, Humans, Neuroprotective Agents, Neurodegenerative Diseases, Nanostructures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review